Metabolic syndrome: An independent risk factor for erectile dysfunction

Saran Sanjay, Gupta Sona Bharti1, Gutch Manish, Philip Rajeev2, Agrawal Pankaj3, Agroiya Puspalata4, Gupta Keshavkumar

Department of Endocrinology, LLRM Medical College, Department of 1Biochemistry and 4Ophthalmology, Subharti Medical College, Meerut, 1Department of Endocrinology, Hormone Care and Research Centre, Ghaziabad, Uttar Pradesh, India, 2Department of Endocrinology, Pushpagiri Medical College Thiruvalla, Kerala

ABSTRACT

Objective: The objective was to determine the role of various components of metabolic syndrome (MetS) as independent risk factor for erectile dysfunction (ED). Materials and Methods: A total of 113 subjects of MetS, as recommended by recent IDF and AHA/NHLBI joint interim statement were selected for study who presented for ED. After doing Anthropometric examination, fasting laboratory assay for fasting plasma glucose (FPG), fasting insulin, hemoglobin A1c, triglyceride (TG), high-density lipoprotein (HDL), low-density lipoprotein (LDL), and 2 h oral glucose tolerance test (OGTT) was done. Erectile function was assessed by completing questions one through five of the International Index of Erectile Function (IIEF-5). A multiple linear regression analysis was carried out on 66 subjects with IIEF-5 score as dependent variable and components of MetS FPG, 2 h OGTT, TG, HDL, and waist circumference as independent variables.

Results: Using a multiple linear regression analysis, we observed that presence of the various components of MetS was associated with ED and a decrease IIEF-5 score and this effect was greater than the effect associated with any of the individual components. Of the individual components of the MetS, HDL ($B = 0.136; P = 0.004$) and FPG ($B = -0.069; P = 0.007$) conferred the strongest effect on IIEF-5 score. However, overall age had most significant effect on IIEF-5 score. Conclusion: It is crucial to formulate strategies and implement them to prevent or control the epidemic of the MetS and its consequences. The early identification and treatment of risk factors might be helpful to prevent ED and secondary cardiovascular disease, including diet and lifestyle interventions.

Key words: Erectile dysfunction, international index of erectile function 5 score, metabolic syndrome

INTRODUCTION

The worldwide epidemic of metabolic syndrome (MetS) has led to a striking increase in the number of people afflicted with the diabetes mellitus, atherosclerotic cardiovascular disease. The MetS or syndrome X is a cluster of interrelated risk factors, which includes central obesity, glucose intolerance, dyslipidemia, and elevated blood pressure. These metabolic abnormalities constitute major risk factors for diabetes mellitus, atherosclerotic cardiovascular disease. At present, five separate definitions for MetS exist the World Health Organization working definition (1999),[1] the European Group for the Study of Insulin Resistance definition (1999),[2] the American Association Of Clinical Endocrinologists position statement (2003),[3] the Adult Treatment Panel III guideline (2005),[4] and the definition from the International Diabetes Federation (IDF) Consensus Group (2005).[5] Although there is considerable debate over the terminology and diagnostic criteria of MetS,[6] Recently, IDF and American Heart Association/National Heart, Lung, and Blood Institute (AHA/NHLBI) representatives held discussions to attempt to resolve the remaining differences between definitions of MetS.[7] Both sides agreed that abdominal obesity should not be a prerequisite for diagnosis but that it is 1 of 5 criteria, so that the presence of any 3 of 5 risk factors constitutes a diagnosis of MetS.[7]
The association of MetS with chronic obstructive pulmonary disease, thyroid disease, and psychiatric disorder is well-described in the literature. Because of the relative paucity of randomized trials on the impact of the MetS on sexual dysfunction, most of the data were collected from cross-sectional or longitudinal studies, where association was observed but not a causation. Gunduz et al. first described the association in between MetS and ED and later it was reinforced by Heidler et al. The MetS leads to endothelial dysfunction also, which leads to a decrease in vascular nitric oxide (NO) levels, with resulting impaired vasodilation. Hypogonadism that may be caused by the MetS can cause ED through altered testosterone (T): Estrogen levels that lead to hypogonadotrophic hypogonadism and by decreasing T level, which impair the NO synthesis. Hyperglycemia, induces a series of cellular events that increase the production of reactive oxygen species like superoxide anion that inactivates NO to form peroxynitrite and also increases oxygen-derived free radicals through activation of protein kinase C and other cellular elements. The increase in free radical concentration also leads to atherosclerotic damage to the vascular walls. Hyperglycemia may also cause glycation of penile cavernosal tissue, that lead to impairment of collagen turnover and later on ED. Hyperglycemia that associated with a proinflammatory states, which can also lead to endothelial dysfunction by upregulation of E-selectin and altered tumor necrosis factor-α and interleukin-10 ratio.

The association of MetS and hypertension, coronary artery disease (CAD), chronic obstructive pulmonary disease, polycystic ovarian disease, thyroid disease, and psychiatric disorder is well-described in the literature. Because of the relative paucity of randomized trials on the impact of the MetS on sexual dysfunction, most of the data were collected from cross-sectional or longitudinal studies, where association was observed but not a causation. Gunduz et al. first described the association in between MetS and ED and later it was reinforced by Heidler et al. In addition, association of MetS and ED was reported in several other studies. Furthermore, investigators still have not completely clarified the effects of the components of the MetS on ED. Furthermore, studies that have focused on the association between MetS and ED in the Indian population are sparse. Therefore, the present study aimed to intensively evaluate the relationship of MetS and ED in Indian men.

**Materials and Methods**

A total of 113 subjects was recruited among those attending outpatient department of Endocrinology and Metabolic Clinic of Lala Lajpat Rai Medical (LLRM) College, Meerut, western Uttar Pradesh between August 2013 and March 2014. Men presented with ED who had three or more criteria to meet the diagnosis of MetS, as recommended by recent IDF and AHA/NHLBI joint interim statement were selected for study. The study was approved by the institutional committee of ethical practice of our institution, and all of the study participants provided written informed consent. Data on the demographic characteristics (e.g. age, education, and occupation), lifestyle characteristics (e.g. smoking, alcohol consumption, and physical activity), health status, and medical history were collected using a standardized Performa. The anthropometric measurements were performed by trained personnel using a standardized protocol. Body weight was taken by electronic weighing machine and height was measured by stadiometer with the subject barefoot fully erect, with the head in the Frankfurt plane; the back of the head, thoracic spine, buttocks, and both heels together with touching the vertical axis of the stadiometer. The body mass index (BMI) was then calculated formula given by Adolphe Quetelet as weight (in kilograms)/height² (in meters). The waist circumference (WC) was measured midway between the lowest rib and the iliac crest to the nearest 0.1 cm. The blood pressure was measured by trained staff nurses using a mercury sphygmomanometer placed on the right arm of the participants, with the participants in a comfortable sitting position after 5 min of rest.

Any men with chronic renal disease, chronic liver disease, cardiovascular disease, peripheral or autonomic neuropathy, mental illness, history of pelvic trauma and surgery, prostatic disease, use of drugs or alcohol abuse, and smoking (both present and past smoking) were excluded from the study. To avoid the effect of drugs on ED, patients with established diabetes mellitus and hypertension were also excluded from the study. Endocrine causes of ED were also excluded. Finally, a total of 66 men with complete data was included in the study.

Venous blood sample was collected from each participant in between 8 am and 9 am after an
overnight fast for laboratory assay. Plasma glucose was measured by a glucose oxidase method. Plasma total cholesterol, high-density lipoprotein (HDL) cholesterol, low-density lipoprotein (LDL) cholesterol, and triglycerides (TGs) were assessed with standard enzymatic spectrophotometric techniques in hospital’s biochemistry laboratory. Haemoglobin A1c (HbA1c) was measured by high-performance liquid chromatography. Total serum testosterone, prolactin, and fasting insulin were measured with chemiluminescence method by abbott archiect i1000SR in endocrinology laboratory. An homeostatic model assessment insulin resistance score (HOMA-IR) was computed with the formula given by matthews et al.: Fasting plasma glucose (FPG) (mmol/l) times fasting serum insulin (mU/l) divided by 22.5.\(^{[28]}\)

**Assessment of erectile dysfunction**

Erectile function was assessed by completing questions one through five of the International Index of Erectile Function (IIEF-5), which is a multidimensional questionnaire consists of 5 questions for assessing ED.\(^{[29]}\) IIEF-5 questionnaire was translated in Hindi for the better understanding. The erectile function score represents the sum of questions one through five of the IIEF-5 questionnaire, with a maximum score of 25; a score <21 indicates ED. The five questions assess erectile confidence, erection firmness, maintenance ability, maintenance frequency, and satisfaction. The severity of ED is classified into five categories as severe (score 5–7), moderate (score 8–11), mild to moderate (score 12–16), mild (score 17–21), and no (score 22–25) ED. Accordingly, out of 66 men 4, 22, 16 and 24 had mild, mild to moderate, moderate and severe ED, respectively.

**Statistical analysis**

For numerical variables, descriptive statistics was performed, and the results were expressed as mean ± standard deviation. Pearson correlation was used for normally distributed variables. A multiple linear regression analysis was carried out with IIEF-5 score as dependent variable and components of MetS FPG, 2 h oral glucose tolerance test (OGTT), TG, HDL, and WC as independent variables. In a multiple linear regression analysis was carried out with IIEF-5 score as dependent variable and components of MetS FPG, 2 h OGTT, TG, HDL, and WC as independent variables. In a multiple linear regression analysis, components of MetS FPG, 2 h OGTT, TG, HDL, and WC were used as continuous variables. The Statistical analysis was performed using the Statistical Package for the Social Sciences Version 20 (SPSS) IBM Corporation, Armonk, NY, USA). A P < 0.05 was considered statistically significant.

**RESULT**

As Table 1 shows baseline characteristic of total 66 participants, all the parameters Age, Wt, BMI, Waist, Hip, WHR, FPG, fasting insulin, HOMA-IR, 2 h OGTT, HbA1c, TG, LDL, and HDL were highly variable in all participants. Mean age and BMI of study population were 43.24 ± 6.2 and 27.95 ± 3.27, respectively. Mean WC, FPG, 2 h OGTT, TG, and HDL were 104.05 ± 7.89, 95.80 ± 15.80, 149.65 ± 24.52, 176.15 ± 50.98, and 45.33 ± 8.29, respectively. Mean IIEF-5 score was 10.17 ± 3.76.

**Correlation between erectile dysfunction and metabolic syndrome components**

By using Pearson correlation analysis, as shown in Table 2, IIEF-5 score is statistically significantly correlated with age and correlation is negative. IIEF-5 score is statistically significantly correlated with components of MetS also; BMI (r = −0.261, P = 0.017); waist (r = −0.216, P = 0.082); Hip (r = −0.434, P = 0.000); WHR (r = −0.507, P = 0.000); 2 h OGTT (r = −0.542, P = 0.000); TG (r = −0.426, P = 0.000)

| Table 1: Baseline characteristics | Range | Minimum | Maximum | Mean | SD |
|----------------------------------|-------|---------|---------|------|----|
| Age (years)                      | 24    | 32      | 56      | 43.24| 6.232|
| Weight (kg)                      | 57    | 62      | 120     | 81.70| 12.885|
| Height (m)                       | 0.28  | 1.58    | 1.86    | 1.7070| 0.06997|
| BMI (kg/m²)                      | 12.65 | 23.18   | 35.83   | 27.95| 3.27 |
| Waist (cm)                       | 36.0  | 92.0    | 128.0   | 104.05| 7.894 |
| Hip (cm)                         | 55.17 | 76.826  | 132.0   | 98.870| 11.973 |
| WHR                              | 0.358 | 0.87    | 1.23    | 1.06 | 0.11 |
| FPG (mg/dl)                      | 56.4  | 68.6    | 125.0   | 95.806| 15.80 |
| Fasting insulin (pmol/L)         | 159.99| 26.30   | 186.30  | 101.04| 49.85 |
| HOMA-IR                          | 7.3   | 0.9     | 8.2     | 3.791 | 2.21 |
| 2 h OGTT (mg/dl)                 | 101.8 | 96.8    | 198.6   | 149.65| 24.52 |
| HbA1c (%)                        | 2.1   | 4.3     | 6.4     | 5.602 | 0.61 |
| TG (mg/dl)                       | 286   | 58      | 344     | 176.15| 50.98 |
| LDL (mg/dl)                      | 33    | 32      | 65      | 45.33 | 8.297 |
| HDL (mg/dl)                      | 176.0 | 66.0    | 242.0   | 158.553| 42.14 |
| IIEF-5 score                     | 14    | 5       | 19      | 10.17 | 3.76 |

SD: Standard deviation, BMI: Body mass index, FPG: Fasting plasma glucose, WHR: Waist to hip ratio, HOMA-IR: Homeostasis model assessment-estimated insulin resistance, OGTT: Oral glucose tolerance test, Hba1c: Glycated hemoglobin, TG: Triglycerides, HDL: High-density lipoprotein, LDL: Low-density lipoprotein, IIEF: International index of erectile function

| Table 2: Correlation between IIEF-5 score and MetS components | Pearson correlation | Significant (1-tailed) |
|-------------------------------------------------------------|---------------------|------------------------|
| Age                                                         | r =−0.525           | P=0.000                |
| BMI                                                         | r =−0.261           | P=0.017                |
| Waist                                                       | r =−0.216           | P=0.082                |
| HDL                                                        | r =−0.434           | P=0.000                |
| FPG                                                         | r =−0.507           | P=0.000                |
| 2 h OGTT                                                    | r =−0.542           | P=0.000                |
| TG                                                          | r =−0.426           | P=0.000                |

BMI: Body mass index, FPG: Fasting plasma glucose, IIEF: International index of erectile function, MetS: Metabolic syndrome, HDL: High-density lipoprotein, OGTT: Oral glucose tolerance test, TG: Triglycerides
HDL \( (r = 0.434, P = 0.000) \); FPG \( (r = -0.507, P = 0.000) \); 2h OGTT \( (r = -0.542, P = 0.000) \); TG \( (r = -0.426, P = 0.000) \).

**Multiple linear regression analysis of various components of metabolic syndrome for erectile dysfunction**

Using a multiple linear regression analysis as shown in Table 3, we also analyzed the effect on IIEF-5 score in relation to the presence of the MetS and the different components of the syndrome separately. The presence of the various components of MetS was associated with ED and a decrease IIEF-5 score, and this effect was greater than the effect associated with any of the individual components. Of the individual components of the MetS, HDL conferred the strongest effect on IIEF-5 score. However, the overall age had most significant effect on IIEF-5 score.

**Discussion**

In the recent years, MetS has received considerable interest because of its association with increasingly common pathophysiologic states such as heart failure, type 2 diabetes mellitus, and ED.\[^{10-32}\] Multiple studies have shown a direct correlation in between various components of the MetS and ED.\[^{13-36}\] In our study, we also observed independent association with components of MetS and ED. By using data from the Massachusetts Male Aging Study, Kupelian et al. have also demonstrated that the presence of MetS is associated with increased ED risk (relative risk = 2.09) even in those with a BMI of <25.\[^{17}\] The cross-sectional analysis of adult participants in the 2001–2004 National Health and Nutrition Examination Survey revealed that poor glycemic control, impaired insulin sensitivity, and the MetS were associated with increased risk of ED.\[^{38}\]

Russo et al. have also found the insulin resistance as an independent predictor of ED.\[^{39}\] Thompson et al. confirmed in his study that ED is a sentinel marker and risk factor for future cardiovascular clinical events.\[^{40}\] Montorsi et al. in the COBRA study observed that in the majority of patients who developed CAD symptoms experienced ED before CAD by an average of 2–3 years.\[^{41}\] As the prevalence of the MetS is increasing at an alarming rate throughout the world. So by identifying high-risk asymptomatic individuals with the MetS could lead to improvements in the prevention and treatment of ED and hence risk of CAD. Taskinen has reported MetS, the most important public health threat of the 21st century.\[^{42}\] Although multiple studies on western ethnicities investigating the associations between MetS and ED have been published, data from Indian population are still limited, and some doubts have not been completely explained. More importantly, identifying the relationships of MetS and ED will be useful to devise effective, population-based, preventive strategies.

Demir et al. observed in his study that IIEF-5 scores significantly decreased as the number of metabolic risk factors increased \((P < 0.001)\).\[^{26}\] In our study, we also found that the mean IIEF-5 scores decreased with an increasing number of MetS components. This finding proved that the severity of ED was associated with an increasing number of metabolic risk factors.

Even though the MetS appears to be an important risk factor for ED but still it is uncertain that which component of the MetS is more frequently associated with ED. In our study, we have demonstrated the relationship in between ED and various components of the MetS separately. We found an association between ED and the metabolic risk factors of abnormal fasting blood glucose (FBG) \((B = 0.68, 95\% \text{ confidence interval [CI]} - 0.118–0.018)\), abnormal HDL \((B = -0.135, 95\% \text{ CI} - 0.044–0.126)\), abnormal WC \((B = 0.034, 95\% \text{ CI} - 0.199–0.131)\), and abnormal TG \((B = -0.002, 95\% \text{ CI} - 0.019–0.015)\). Demir et al. and Lee et al. also reported a significant association between ED and abnormal FBG.\[^{20,43}\] Yang et al. has showed that Diabetes mellitus alone, which is a component of MetS, is associated with presence and severity of ED; therefore, the

**Table 3: Multiple linear regression analysis of various components of MetS for IIEF-5 score**

| Model | Unstandardized coefficients | Standardized coefficients | t | Significant | 95.0% CI for B |
|-------|-----------------------------|---------------------------|---|------------|----------------|
|       | B                           | SE                        | Beta |           | Lower bound | Upper bound |
| Constant | 25.295                     | 4.944                     |      | 5.111      | 0.000       | 15.388       | 35.202       |
| Age    | -0.252                      | 0.052                     | -0.416 | -4.843   | 0.000       | -0.356       | -0.148       |
| BMI    | 0.027                       | 0.125                     | 0.024 | 0.218     | 0.828       | -0.223       | 0.278        |
| Waist  | -0.020                      | 0.051                     | -0.042 | -0.394   | 0.695       | -0.083       | 0.123        |
| TG     | -0.004                      | 0.008                     | -0.051 | -0.462   | 0.646       | -0.020       | 0.013        |
| HDL    | 0.134                       | 0.045                     | 0.295 | 2.976     | 0.004       | 0.044        | 0.224        |
| FPG    | -0.069                      | 0.025                     | -0.291 | -2.816   | 0.007       | -0.19        | -0.020       |
| 2h OGTT| -0.039                      | 0.014                     | -0.255 | -2.761   | 0.008       | -0.068       | -0.011       |

MetS: Metabolic syndrome, HDL: High-density lipoprotein, OGTT: Oral glucose tolerance test, TG: Triglycerides, IIEF: International index of erectile function, CI: Confidence interval, SE: Standard error, BMI: Body mass index, FPG: Fasting plasma glucose
association in between abnormal FBG and ED is appear to be logical.[35] In addition, our results were not in line with those from some similar studies. Demir et al. reported that an abnormal WC was also a significant risk factor predicting the risk of ED. However, we did not find this relationship in our study, although that might be attributable to the higher mean WC in our study.

Our findings indicate that the MetS and ED are common health problems affecting the male quality-of-life in India.

CONCLUSION

Thus, it is critical to establish strategies to prevent or control the epidemic trend of the MetS and its consequences. The early identification and treatment of at-risk individuals could help target interventions to improve ED and secondary cardiovascular disease, including weight management, lifestyle interventions, and physical activity. Several studies have shown the efficacy of the intervention. Esposito et al. found a Mediterranean-style diet rich in whole grain, fruits, vegetables, legumes, and walnut and olive oil might be effective in reducing the prevalence of ED in men with the MetS.[44]

ACKNOWLEDGMENT

The authors thank The Principal, LLRM Medical College for supporting endocrinology laboratory for doing all investigations free of cost. No other potential conflicts of interests relevant to this article were reported.

REFERENCES

1. Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: Diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 1998;15:539-53.
2. Balkau B, Charles MA. Comment on the provisional report from the WHO consultation. European Group for the Study of Insulin Resistance (EGIR) Diabet Med 1999;16:442-3.
3. Einhorn D, Reaven GM, Cobin RH, Ford E, Ganda OP, Handelsman Y, et al. American College of Endocrinology position statement on the insulin resistance syndrome. Endocr Pract 2003;9:237-52.
4. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001;285:2486-97.
5. Adams RJ, Appleton S, Wilson DH, Taylor AW, Dal Grande E, Chittleborough C, et al. Population comparison of two clinical approaches to the metabolic syndrome: Implications of the new International Diabetes Federation consensus definition. Diabetes Care 2005;28:2777-9.
6. Parikh RM, Mohan V. Changing definitions of metabolic syndrome. Indian J Endocrinol Metab 2012;16:7-12.
7. Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, et al. Harmonizing the metabolic syndrome: A joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 2009;120:1640-5.
8. Krane RJ, Goldstein I, Saenz de Tejada I. Impotence. N Engl J Med 1989;321:1648-59.
9. NIH Consensus Conference. Impotence. NIH Consensus Development Panel on Impotence. JAMA 1993;270:83-90.
10. Korenman SG. New insights into erectile dysfunction: A practical approach. Am J Med 1998;105:135-44.
11. Fugl-Meyer AR, Lodnert G, Brännholm IB, Fugl-Meyer KS. On life satisfaction in male erectile dysfunction. Int J Impot Res 1997;9:141-8.
12. Nehra A, Azadzoi KM, Moreland RB, Pabby A, Siroky MB, Krane RJ, et al. cavernosal expandability is an erectile tissue mechanical property which predicts trabecular histology in an animal model of vasculogenic erectile dysfunction. J Urol 1998;159:2229-36.
13. Beckman JA, Goldfine AB, Gordon MB, Creager MA. Ascorbate restores endothelium-dependent vasodilation impaired by acute hyperglycemia in humans. Circulation 2001;103:1618-23.
14. Nishikawa T, Edelstein D, Du XL, Yamagishi S, Matsumura T, Kaneda Y, et al. Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage. Nature 2000;404:787-90.
15. Huang PL. A comprehensive definition for metabolic syndrome. Dis Model Mech 2009;2:231-7.
16. Jiaan DB, Seftel AD, Fogarty J, Hampel N, Cruz W, Pomerantz J, et al. Age-related increase in an advanced glycation end product in penile tissue. World J Urol 1995;13:369-75.
17. Araña Rosainz Mde J, Ojeda MO, Acosta JR, Elías-Calles LC, González NO, Herrera OT, et al. Imbalanced low-grade inflammation and endothelial activation in patients with type 2 diabetes mellitus and erectile dysfunction. J Sex Med 2011;8:2017-30.
18. Osuji CU, Omejua EG. Prevalence and characteristics of the metabolic syndrome among newly diagnosed hypertensive patients. Indian J Endocrinol Metab 2012;16 Suppl 1:S104-9.
19. Mahalle N, Garg MK, Naik SS, Kulkarni MV. Association of metabolic syndrome with severity of coronary artery disease. Indian J Endocrinol Metab 2014;18:708-14.
20. Naik D, Joshi A, Paul TV, Thomas N. Chronic obstructive pulmonary disease and the metabolic syndrome: Consequences of a dual threat. Indian J Endocrinol Metab 2014;18:608-16.
21. Shabir I, Ganie MA, Zargar MA, Bhat D, Mir MM, Jan A, et al. Prevalence of metabolic syndrome in the family members of women with polycystic ovary syndrome from North India. Indian J Endocrinol Metab 2014;18:364-9.
22. Ogbera AO, Kuku S, Dada O. The metabolic syndrome in thyroid disease: A report from Nigeria. Indian J Endocrinol Metab 2012;16:417-22.
23. Bajaj S, Varma A, Srivastava A, Verma AK. Association of metabolic syndrome with schizophrenia. Indian J Endocrinol Metab 2013;17:890-5.
24. Gündüz MI, Gümüs BH, Sekuri C. Relationship between metabolic syndrome and erectile dysfunction. J Sex Med 2014;11:2017-30.
25. Heidler S, Temml C, Broessner C, Mock K, Rauchenwald M, Madersbacher S, et al. Is the metabolic syndrome an independent risk factor for erectile dysfunction? J Urol 2007;177:651-4.
26. Demir T, Demir O, Kefi A, Comlekci A, Yesil S, Eskin A. Prevalence of erectile dysfunction in patients with metabolic syndrome. Int J Impot Res 2006;18:385-8.
27. Bal K, Oder M, Sahin AS, Karatas CT, Demir O, Can E, et al. Prevalence of metabolic syndrome and its association with erectile dysfunction.
dysfunction among urologic patients: Metabolic backgrounds of erectile dysfunction. Urology 2007;69:356-60.

28. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: Insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985;28:412-9.

29. Rosen RC, Cappelleri JC, Gendrano N 3rd. The International Index of Erectile Function (IIEF): A state-of-the-science review. Int J Impot Res 2002;14:226-44.

30. Ingelsson E, Arnlöv J, Lind L, Sundström J. Metabolic syndrome and risk for heart failure in middle-aged men. Heart 2006;92:1409-13.

31. Imam SK, Shahid SK, Hassan A, Alvi Z. Frequency of the metabolic syndrome in type 2 diabetic subjects attending the diabetes clinic of a tertiary care hospital. J Pak Med Assoc 2007;57:239-42.

32. Bansal TC, Guay AT, Jacobson J, Woods BO, Nesto RW. Incidence of metabolic syndrome and insulin resistance in a population with organic erectile dysfunction. J Sex Med 2005;2:96-103.

33. Esposito K, Giugliano D. Obesity, the metabolic syndrome, and sexual dysfunction in men. Clin Pharmacol Ther 2011;90:169-73.

34. Al-Hunayan A, Al-Mutar M, Kehinde EO, Thalib L, Al-Ghorory M. The prevalence and predictors of erectile dysfunction in men with newly diagnosed with type 2 diabetes mellitus. BJU Int 2007;99:130-4.

35. Yang G, Pan C, Lu J. Prevalence of erectile dysfunction among Chinese men with type 2 diabetes mellitus. Int J Impot Res 2010;22:310-7.

36. Roumeguère T, Wespes E, Carpentier Y, Hoffmann P, Schulman CC. Erectile dysfunction is associated with a high prevalence of hyperlipidemia and coronary heart disease risk. Eur Urol 2003;44:355-9.

37. Kupelian V, Shabsigh R, Araujo AB, O’Donnell AB, McKirland JB. Erectile dysfunction as a predictor of the metabolic syndrome in aging men: Results from the Massachusetts Male Aging Study. J Urol 2006;176:222-6.

38. Weinberg AE, Eisenberg M, Patel CJ, Chertow GM, Leppert JT. Diabetes severity, metabolic syndrome, and the risk of erectile dysfunction. J Sex Med 2013;10:3102-9.

39. Russo GI, Cimino S, Fragala E, Privitera S, La Vignera S, Condorelli R, et al. Insulin resistance is an independent predictor of severe lower urinary tract symptoms and of erectile dysfunction: Results from a cross-sectional study. J Sex Med 2014;11:2074-82.

40. Thompson IM, Tangen CM, Goodman PJ, Probstfield JL, Moinpour CM, Colman CA. Erectile dysfunction and subsequent cardiovascular disease. JAMA 2005;294:2996-3002.

41. Montorsi P, Ravagnani PM, Galli S, Rotatori F, Veglia F, Briganti A, et al. Association between erectile dysfunction and coronary artery disease. Role of coronary clinical presentation and extent of coronary vessels involvement: The COBRA trial. Eur Heart J 2006;27:2632-9.

42. Taskinen MR. Is metabolic syndrome the main threat to human health in the twenty-first century? Arterioscler Thromb Vasc Biol 2007;27:2275.

43. Lee YC, Liu CC, Huang CN, Li WM, Wu WJ, Yeh HC, et al. The potential impact of metabolic syndrome on erectile dysfunction in aging Taiwanese males. J Sex Med 2010;7:3127-34.

44. Esposito K, Ciotola M, Giugliano F, De Sio M, Giugliano G, D’armiento M, et al. Mediterranean diet improves erectile function in subjects with the metabolic syndrome. Int J Impot Res 2006;18:405-10.

Cite this article as: Sanjay S, Bharti GS, Manish G, Rajeev P, Pankaj A, Puspalata A, Keshavkumar G. Metabolic syndrome: An independent risk factor for erectile dysfunction. Indian J Endocr Metab 2015;19:277-82.

Source of Support: Nil, Conflict of Interest: None declared.